Long non-coding RNA lncAPAT promotes atherosclerotic plaque instability by targeting ribosomal protein L22

Abstract

Background: Long non-coding RNAs (lncRNAs) regulate macrophage inflammation and atherosclerotic plaque stability, but mechanisms need comprehensive investigations.

Methods: Whole-transcriptome sequencing was used to identify a novel human-specific lncRNA, lncAPAT (atherosclerotic plaque instability-associated transcript), in the peripheral blood of patients with coronary artery disease (CAD; n = 5) with mixed plaques on coronary computed tomography angiography (CCTA). LncAPAT was quantified using quantitative real-time polymerase chain reaction in the discovery cohort and independently validated in patients with coronary mixed plaques by CCTA (n = 22) and in patients with acute ST-segment elevation myocardial infarction (STEMI; n = 22). Myeloid cell-specific lncAPAT knock-in mice were generated and injected with recombinant adeno-associated virus of murine proprotein convertase subtilisin/kexin type 9 to induce atherosclerosis and explore the effects of lncAPAT on inflammation and plaque instability. Macrophages were cultured to evaluate lncAPAT function in vitro. Chromatin isolation by RNA purification and sequencing and RNA immunoprecipitation assays were used to identify potential targets of lncAPAT.

Results: LncAPAT expression was highly expressed in the peripheral blood of CAD and STEMI patients compared with the control individuals. Mice with myeloid cell-specific lncAPAT knock-in showed an increased plaque burden (2.7-fold), elevated macrophage counts (2.4-fold), and higher matrix metalloproteinase (MMP) expression (3.3-fold for MMP9, 2.0-fold for MMP2) in thoracic aortic plaques. In vitro, lncAPAT significantly promoted the inflammatory responses, adhesive capacity and cholesterol accumulation of macrophages, and decreased the cholesterol efflux ratio. LncAPAT interacted with the promoter of the ribosomal protein L22 gene (RPL22) and inhibited RPL22 transcription. RPL22 inhibition significantly increased the expression of inflammatory cytokines. The RPL22 protein directly interacted with monocyte chemoattractant protein-1 (MCP-1) mRNA and decreased MCP-1 expression. Furthermore, RPL22 expression in the peripheral blood was lower in CAD and STEMI patients than in control individuals.

Conclusions: LncAPAT promoted the macrophage inflammatory response by inhibiting RPL22 transcriptional activity, contributing to plaque instability.

Keywords

atherosclerosis / cardiovascular disease / inflammation / long non-coding RNA / macrophage

References

[1] Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145(3): 341-355.

[2] Tabas I, Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis. Immunity. 2017; 47(4): 621-634.

[3] Khyzha N, Alizada A, Wilson MD, Fish JE. Epigenetics of atherosclerosis: emerging mechanisms and methods. Trends Mol Med. 2017; 23(4): 332-347.

[4] Li S, He RC, Wu SG, et al. LncRNA PSMB8-AS1 instigates vascular inflammation to aggravate atherosclerosis. Circ Res. 2024; 134(1): 60-80.

[5] Sun C, Fu Y, Gu X, et al. Macrophage-enriched lncRNA RAPIA: a novel therapeutic target for atherosclerosis. Arterioscler Thromb Vasc Biol. 2020; 40(6): 1464-1478.

[6] Zhang W, Zhao J, Deng L, et al. INKILN is a novel long noncoding RNA promoting vascular smooth muscle inflammation via scaffolding MKL1 and USP10. Circulation. 2023; 148(1): 47-67.

[7] Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation. 2004; 109(1): 14-17.

[8] Hou ZH, Lu B, Gao Y, et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging. 2012; 5(10): 990-999.

[9] Ostrom MP, Gopal A, Ahmadi N, et al. Mortality incidence and the severity of coronary atherosclerosis assessed by computed tomography angiography. J Am Coll Cardiol. 2008; 52(16): 1335-1343.

[10] Araki M, Park SJ, Dauerman HL, et al. Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nat Rev Cardiol. 2024; 21(6): 348.

[11] Maurovich-Horvat P, Schlett CL, Alkadhi H, et al. Differentiation of early from advanced coronary atherosclerotic lesions: systematic comparison of CT, intravascular US, and optical frequency domain imaging with histopathologic examination in ex vivo human hearts. Radiology. 2012; 265(2): 393-401.

[12] Bjørklund MM, Hollensen AK, Hagensen MK, et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res. 2014; 114(10): 1684-1689.

[13] Chao ML, Luo S, Zhang C, et al. S-nitrosylation-mediated coupling of G-protein α-2 with CXCR5 induces Hippo/YAP-dependent diabetes-accelerated atherosclerosis. Nat Commun. 2021; 12(1): 4452.

[14] Cochain C, Vafadarnejad E, Arampatzi P, et al. Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res. 2018; 122(12): 1661-1674.

[15] Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016; 118(4): 653-667.

[16] Das AS, Basu A, Mukhopadhyay R. Ribosomal proteins: the missing piece in the inflammation puzzle?. Mol Cell Biochem. 2025; 480(2): 785-797.

[17] Das AS, Basu A, Kumar R, et al. Post-transcriptional regulation of C-C motif chemokine ligand 2 expression by ribosomal protein L22 during LPS-mediated inflammation. FEBS J. 2020; 287(17): 3794-3813.

[18] Czamara K, Majka Z, Sternak M, et al. Distinct chemical changes in abdominal but not in thoracic aorta upon atherosclerosis studied using fiber optic Raman spectroscopy. Int J Mol Sci. 2020; 21(14): 4838.

[19] Benvenuti LA, Onishi RY, Gutierrez PS, et al. Different patterns of atherosclerotic remodeling in the thoracic and abdominal aorta. Clinics (Sao Paulo). 2005; 60(4): 355-360.

[20] Rekhter MD, Zhang K, Narayanan AS, et al. Type I collagen gene expression in human atherosclerosis. Localization to specific plaque regions. Am J Pathol. 1993; 143(6): 1634-1648.

[21] Singh D, Rai V, Agrawal DK. Regulation of collagen I and collagen III in tissue injury and regeneration. Cardiol Cardiovasc Med. 2023; 7(1): 5-16.

[22] McKellar GE, McCarey DW, Sattar N, et al. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009; 6(7): 410-417.

[23] Möst J, Schwaeble W, Drach J, Sommerauer A, Dierich MP. Regulation of the expression of ICAM-1 on human monocytes and monocytic tumor cell lines. J Immunol. 1992; 148(6): 1635-1642.

[24] Gautier EL, Shay T, Miller J, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012; 13(11): 1118-1128.

[25] Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009; 325(5940): 612-616.

[26] Rosas M, Davies LC, Giles PJ, et al. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science. 2014; 344(6184): 645-648.

[27] Tall AR, Yvan-Charvet L. Cholesterol inflammation and innate immunity. Nat Rev Immunol. 2015; 15(2): 104-116.

[28] Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019; 124(3): 315-327.

[29] Jansen J, Bohnsack KE, Böhlken-Fascher S, et al. The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress. Cell Rep. 2024; 43(1):114610.

[30] Li HY, Wang M, Jiang X, et al. CRISPR screening uncovers nucleolar RPL22 as a heterochromatin destabilizer and senescence driver. Nucleic Acids Res. 2024; 52(20): 11481-11499.

[31] Staszewski J, Lazarewicz N, Konczak J, et al. UPF1-from mRNA degradation to human disorders. Cells. 2023; 12(3): 419.

[32] He C, Kim HI, Park J, et al. The role of immune cells in different stages of atherosclerosis. Int J Med Sci. 2024; 21(6): 1129-1143.

[33] Szilágyi M, Pös O, Márton É, et al. Circulating cell-free nucleic acids: main characteristics and clinical application. Int J Mol Sci. 2020; 21(18): 6827.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.